Our findings reveal that MYBL2 is increased in gliomas and that overexpression of MYBL2 is associated with poorer survival and prognosis, implying that MYBL2 might be used as an independent glioma prognostic biomarker. Here, MYBL2 is linked to central nervous system cancer.